INTRODUCTION
Hereditary haemochromatosis (HH) is the most frequent autosomal-recessive disorder in Caucasians usually caused by a homozygous C282Y mutation in the HFE gene. 1 This mutation leads to an abnormal increased iron absorption in the gut. Typically patients developing symptoms of iron overload are between 30 and 50 years of age and predominantly men. The classical triad of liver cirrhosis, diabetes and hyperpigmentation is however rare in clinical practice nowadays. In fact, the most frequent symptoms leading to diagnosis are currently arthralgias and clinically silent elevated liver enzymes. 2 In 1964, Schumacher recognised arthritis as a leading clinical symptom in HH patients. 3 Recent evidence suggests that approximately 30-50% of HH patients develop an associated arthropathy. The typical location of arthritis is the second and third metacarpophalangeal (MCP) joint, but hip, knee and ankle joints can also be affected. 4 Misdiagnosis as rheumatoid arthritis or idiopathic osteoarthritis (OA) is not uncommon. About one-third of HH patients show radiographic signs of chondrocalcinosis, although pseudogout is a rather uncommon clinical presentation. In affected MCP joints, conventional radiographs show hooklike osteophytes, cysts and sometimes even erosions. 5 Little is known about risk factors for development of HH arthropathy nor do we fully understand the pathophysiology. Apart from the degree of iron overload itself, only women's sex and age are associated with joint involvement in HH. 6 7 Thus, we are currently not sufficiently able to prevent or even predict arthropathy in HH patients. Vascular adhesion molecule 1 (VCAM-1) has recently been implicated as a risk factor for degenerative arthritis. While the exact pathophysiological role of VCAM-1 is unclear, high serum levels of VCAM-1 are strongly associated with the development of idiopathic OA. [8] [9] [10] In this study, we thus investigated VCAM-1 serum levels in a large cohort of HH patients and correlated these with the clinical manifestations including arthropathy.
METHODS
Details of inclusion criteria, clinical assessment, radiographic scoring, VCAM-1 measurements and statistical analyses are given in online supplementary information.
RESULTS Demographics
Clinical details for the HH and control group are given in table 1. Briefly, we included 147 HH patients and 147 age-and sex-matched controls.
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VCAM-1 serum levels in matched controls and correlations to possible confounders VCAM-1 levels in the control group were not significantly correlated with age (r=0.119, p=0.151), diabetes (r=0.03, p=0.790) or high blood pressure (r=0.097, p=0.243) and only very weakly correlated with body mass index (BMI) (r=0.169, p=0.043). There was no significant correlation between VCAM-1 levels and the number of smokers (r=0.138, p=0.130) nor their pack years (r=0.120, p=0.191).
VCAM-1 serum levels in HH patients with or without arthropathy
We found significantly elevated VCAM-1 serum levels in HH patients (mean level 913±456 ng/ml) as compared to matched controls (mean level 654±451 ng/ml, p<0.0001). Interestingly, VCAM-1 levels were higher in HH patients with arthropathy (n=81, 55.1%; mean 1049±527 ng/ml) as compared to HH patients without arthropathy (n=66, 44.9%; mean 746±272 ng/ml, p<0.0001; figure 1A ). We also compared patients with and without arthropathy to the matched controls: VCAM-1 levels were significantly lower in controls than in HH patients with and without arthropathy (p<0.0001 for both comparisons).
We analysed VCAM-1 levels in those patients who have had a joint replacement surgery of the knee or hip. VCAM-1 was once more significantly higher in patients who had received joint replacement surgery compared to those HH patients without joint replacement (mean 985±320 vs 900±477 ng/ml, p=0.028; figure 1B) .
The relationship between VCAM-1 and HH arthropathy was further investigated using the radiographic haemochromatosis arthropathy score. 12 There was a moderate but highly significant correlation between VCAM-1 levels and the MCP 2/3 x-ray score (r=0.36, p<0.0001; figure 2).
The independent effect of increased VCAM-1 in haemochromatosis arthropathy after controlling for possible confounders
The primary question was, if VCAM-1 was independently associated with arthropathy in our patient cohort after correcting for possible confounders. We chose a regression model and defined the previously described radiographic scoring method specifically developed and validated in patients with HH arthropathy as outcome variable. The model allowed investigation of VCAM-1 as primary measure while controlling for age, diabetes and BMI.
Age, diabetes and BMI explained 24% of the variance in the x-ray score. After introduction of VCAM-1 into the model, the total variance explained by the model increased to 28.2% (F (4, 142)=13.94, p<0.0001). VCAM-1 therefore added statistically significant input to the variance in arthropathy, even after controlling for age, diabetes and BMI (R 2 =0.041, F change (1, 14)=8.20, p=0.005). In the final model, only VCAM-1 (β=0.22, p=0.005) and age (β=0.37, p<0.0001) were significantly associated with the development of arthropathy.
Since our analyses suggested a close correlation between VCAM-1 and arthropathy on the one hand and between age and arthropathy on the other hand, we decided to perform further analyses. We explored the relationship between VCAM-1 and arthropathy while controlling for age using partial correlation. There was a strong correlation between VCAM-1 and the x-ray score, even after controlling for age, r=0.27, p<0.0001. Further inspections of this model suggested that the strength of the relationship between VCAM-1 and arthropathy was largely independent from age (zero-order correlation; r=0.36).
Correlation of VCAM-1 with arthropathy is largely independent of liver disease in HH patients VCAM-1 serum levels were higher in patients with elevated liver enzymes at diagnosis (mean 1046±521 vs 827±388 ng/ml, p=0.003) and advanced liver disease (mean 1303±737 vs 817±287 ng/ml, p<0.0001). Again, we applied partial correlation in order to explore the relationship between VCAM-1 and arthropathy while controlling for advanced liver disease. There was a strong correlation between VCAM-1 and the x-ray score, even after controlling for advanced liver disease (r=0.222, p=0.008).
DISCUSSION
Joint pain and fatigue are the most common presenting symptoms in HH nowadays and many patients also show biochemical evidence of liver injury. 2 There is no clear evidence why some patients develop arthropathy and others do not. At the same time, therapeutic phlebotomy prevents liver cirrhosis but does not affect arthropathy. 13 Contrary to all other clinical manifestations, arthropathy can even develop after initiation of phlebotomy treatment. Only women's age and sex seem to predict the presence of articular damage, but we know that traditional risk factors such as diabetes and BMI are not associated with HH arthropathy. 4 The causes of haemochromatosis arthropathy are currently enigmatic. Iron deposition is found in haemochromatosis joints but this is an unspecific phenomenon. 6 7 14 One significant finding is premature chrondrocalcinosis of wrists and knee joints, although pseudogout attacks are uncommon in clinical practice. Nevertheless, cartilage calcification may play a role in degenerative arthritis in HH. Histologically, mostly mild synovitis is observed similar to idiopathic OA. The only distinguishing feature is a more prominent infiltration of neutrophils. 15 VCAM-1 is expressed on the endothelium of blood vessels facilitating leukocyte adhesion and recruitment into inflamed tissues. 16 In degenerative and inflammatory arthritis, VCAM-1 is locally expressed on endothelial cells, macrophages, fibroblasts and chondrocytes. 17 Pro-inflammatory mediators such as interleukin 1 can increase VCAM-1 expression. 18 Furthermore, hyaluron released during articular cartilage damage also induces VCAM-1 production. 19 Interaction of chondrocytes and immune cells may also be VCAM-1 dependent. 17 Neutralisation of VCAM-1 reduces joint inflammation in murine models of arthritis. 20 Thus, VCAM-1 is a possible mediator of articular damage.
In a recent study, we found elevated VCAM-1 but none of the other leukocyte adhesion molecule serum levels were independently associated with the development of knee and hip OA. 13 Although this study needs replication, VCAM-1 may emerge as one of few predictors of large joint OA apart from known ones such as women's age, sex and overweight. Elevated VCAM-1 levels have also been linked to the presence of hand OA in a cohort of Chuvashian patients. 8 The pathophysiological link between VCAM-1 and degenerative arthritis is however currently unknown.
Our cohort of HH patients reflects the current clinical situation. Two-thirds of patients were men, 55% presented with arthropathy and 16% already had joint replacement. We found significantly elevated serum VCAM-1 levels in HH patients as compared to age-and sex-matched controls. Interestingly, VCAM-1 levels correlated well with radiographic severity. Furthermore, VCAM-1 levels were also elevated significantly in the most severely affected HH patients having undergone joint replacement surgery. Multivariate analysis revealed the highly significant independent association of VCAM-1 levels with HH arthropathy after controlling for diabetes, BMI and age. Furthermore, in our analysis, VCAM-1 levels were partially independent of the presence of advanced liver disease, even though severity of HH itself might explain elevated VCAM-1 levels.
Thus, VCAM-1 may indeed link chronic iron overload and arthropathy in HH patients although causal relationships are yet unclear. We also do not know whether VCAM-1 levels are elevated in untreated newly diagnosed HH patients and more importantly whether VCAM-1 levels could predict development of HH arthropathy.
In summary, we have shown an independent and highly significant association of VCAM-1 levels and HH arthropathy. Further prospective studies are needed to validate our findings of a new biomarker in HH patients. 
